August 30, 2022 | ~Home Feature| Press Release

Castle Creek Biosciences Announces Publication of Preclinical Study for Potential In Vivo Gene Therapy in Nature Communications

The cell and gene therapy company’s lead in vivo candidate uses lentiviral vector delivery to correct metabolic disorder in large animal model of hereditary tyrosinemia type-1

Read More

May 25, 2022 | ~Home Feature| Press Release

Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline  

Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa

Read More

May 02, 2022 | Events

American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Hybrid Conference

Read More

May 02, 2022 | Events

Society of Investigative Dermatology (SID) Annual Meeting

Read More

May 02, 2022 | Events

BIO International Convention

Read More

April 16, 2022 | Events

Society of Pediatric Dermatology (SPD) Annual Meeting

Read More

January 10, 2022 | ~Home Feature| Press Release

Castle Creek Biosciences Acquires Novavita Thera to Expand Innovative Cell and Gene Therapy Platform

Company adds in vivo capabilities to existing ex vivo approach for development of novel gene therapies

Read More

October 21, 2021 | ~Home Feature| Press Release

Castle Creek Biosciences Awarded FDA Orphan Products Development Grant to Support DeFi-RDEB, a Pivotal Phase 3 Study of FCX-007 Investigational Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

RDEB is a devastating, rare genetic blistering disease with no FDA-approved treatments currently available

Read More

October 14, 2021 | Media Coverage

U.S. Food and Drug Administration Bulletin

FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments

Read More

September 29, 2021 | Press Release

Castle Creek Biosciences Expands its Innovative Gene Therapy Platform for Rare Genetic Connective Tissue Disorders through Research Collaboration with Mayo Clinic

Research to focus on osteogenesis imperfecta and classical Ehlers-Danlos syndrome, debilitating disorders with no FDA-approved treatments

Read More